Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer.

Remmerie M, Janssens V.

Front Oncol. 2019 Jun 4;9:462. doi: 10.3389/fonc.2019.00462. eCollection 2019. Review.

2.

Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis.

Elgendy M, Cirò M, Hosseini A, Weiszmann J, Mazzarella L, Ferrari E, Cazzoli R, Curigliano G, DeCensi A, Bonanni B, Budillon A, Pelicci PG, Janssens V, Ogris M, Baccarini M, Lanfrancone L, Weckwerth W, Foiani M, Minucci S.

Cancer Cell. 2019 May 13;35(5):798-815.e5. doi: 10.1016/j.ccell.2019.03.007. Epub 2019 Apr 25.

PMID:
31031016
3.

De Novo Mutations Affecting the Catalytic Cα Subunit of PP2A, PPP2CA, Cause Syndromic Intellectual Disability Resembling Other PP2A-Related Neurodevelopmental Disorders.

Reynhout S, Jansen S, Haesen D, van Belle S, de Munnik SA, Bongers EMHF, Schieving JH, Marcelis C, Amiel J, Rio M, Mclaughlin H, Ladda R, Sell S, Kriek M, Peeters-Scholte CMPCD, Terhal PA, van Gassen KL, Verbeek N, Henry S, Schwoerer JS, Malik S, Revencu N, Ferreira CR, Macnamara E, Braakman HMH, Brimble E, Ruzhnikov MRZ, Wagner M, Harrer P, Wieczorek D, Kuechler A, Tziperman B, Barel O, de Vries BBA, Gordon CT, Janssens V, Vissers LELM.

Am J Hum Genet. 2019 Feb 7;104(2):357. doi: 10.1016/j.ajhg.2019.01.003. No abstract available.

4.

De Novo Mutations Affecting the Catalytic Cα Subunit of PP2A, PPP2CA, Cause Syndromic Intellectual Disability Resembling Other PP2A-Related Neurodevelopmental Disorders.

Reynhout S, Jansen S, Haesen D, van Belle S, de Munnik SA, Bongers EMHF, Schieving JH, Marcelis C, Amiel J, Rio M, Mclaughlin H, Ladda R, Sell S, Kriek M, Peeters-Scholte CMPCD, Terhal PA, van Gassen KL, Verbeek N, Henry S, Scott Schwoerer J, Malik S, Revencu N, Ferreira CR, Macnamara E, Braakman HMH, Brimble E, Ruzhnikov MRZ, Wagner M, Harrer P, Wieczorek D, Kuechler A, Tziperman B, Barel O, de Vries BBA, Gordon CT, Janssens V, Vissers LELM.

Am J Hum Genet. 2019 Jan 3;104(1):139-156. doi: 10.1016/j.ajhg.2018.12.002. Epub 2018 Dec 27. Erratum in: Am J Hum Genet. 2019 Feb 7;104(2):357.

5.

Vps34/PI3KC3 deletion in kidney proximal tubules impairs apical trafficking and blocks autophagic flux, causing a Fanconi-like syndrome and renal insufficiency.

Grieco G, Janssens V, Gaide Chevronnay HP, N'Kuli F, Van Der Smissen P, Wang T, Shan J, Vainio S, Bilanges B, Jouret F, Vanhaesebroeck B, Pierreux CE, Courtoy PJ.

Sci Rep. 2018 Sep 20;8(1):14133. doi: 10.1038/s41598-018-32389-z.

6.

Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late.

Remmerie M, Janssens V.

Int J Mol Sci. 2018 Aug 13;19(8). pii: E2380. doi: 10.3390/ijms19082380. Review.

7.

Physiologic functions of PP2A: Lessons from genetically modified mice.

Reynhout S, Janssens V.

Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):31-50. doi: 10.1016/j.bbamcr.2018.07.010. Epub 2018 Jul 18. Review.

PMID:
30030003
8.

Protein kinase D displays intrinsic Tyr autophosphorylation activity: insights into mechanism and regulation.

Cobbaut M, Derua R, Parker PJ, Waelkens E, Janssens V, Van Lint J.

FEBS Lett. 2018 Jul;592(14):2432-2443. doi: 10.1002/1873-3468.13171. Epub 2018 Jul 23.

9.

Dephosphorylation of the HIV-1 restriction factor SAMHD1 is mediated by PP2A-B55α holoenzymes during mitotic exit.

Schott K, Fuchs NV, Derua R, Mahboubi B, Schnellbächer E, Seifried J, Tondera C, Schmitz H, Shepard C, Brandariz-Nuñez A, Diaz-Griffero F, Reuter A, Kim B, Janssens V, König R.

Nat Commun. 2018 Jun 8;9(1):2227. doi: 10.1038/s41467-018-04671-1.

10.

In vivo pieces of the PP2A onco-puzzle fallen into place.

Meeusen B, Janssens V.

Oncoscience. 2017 Dec 20;4(11-12):154-155. doi: 10.18632/oncoscience.384. eCollection 2017 Nov. No abstract available.

11.

PP2A Inactivation Mediated by PPP2R4 Haploinsufficiency Promotes Cancer Development.

Sents W, Meeusen B, Kalev P, Radaelli E, Sagaert X, Miermans E, Haesen D, Lambrecht C, Dewerchin M, Carmeliet P, Westermarck J, Sablina A, Janssens V.

Cancer Res. 2017 Dec 15;77(24):6825-6837. doi: 10.1158/0008-5472.CAN-16-2911. Epub 2017 Oct 18.

12.

Tumor suppressive protein phosphatases in human cancer: Emerging targets for therapeutic intervention and tumor stratification.

Meeusen B, Janssens V.

Int J Biochem Cell Biol. 2018 Mar;96:98-134. doi: 10.1016/j.biocel.2017.10.002. Epub 2017 Oct 12. Review.

PMID:
29031806
13.

Fructose-1,6-bisphosphate couples glycolytic flux to activation of Ras.

Peeters K, Van Leemputte F, Fischer B, Bonini BM, Quezada H, Tsytlonok M, Haesen D, Vanthienen W, Bernardes N, Gonzalez-Blas CB, Janssens V, Tompa P, Versées W, Thevelein JM.

Nat Commun. 2017 Oct 13;8(1):922. doi: 10.1038/s41467-017-01019-z.

14.

Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo.

Lambrecht C, Libbrecht L, Sagaert X, Pauwels P, Hoorne Y, Crowther J, Louis JV, Sents W, Sablina A, Janssens V.

Oncogene. 2018 Jan 25;37(4):544-552. doi: 10.1038/onc.2017.350. Epub 2017 Oct 2.

PMID:
28967903
15.

Cellular uptake of proMMP-2:TIMP-2 complexes by the endocytic receptor megalin/LRP-2.

Johanns M, Lemoine P, Janssens V, Grieco G, Moestrup SK, Nielsen R, Christensen EI, Courtoy PJ, Emonard H, Marbaix E, Henriet P.

Sci Rep. 2017 Jun 28;7(1):4328. doi: 10.1038/s41598-017-04648-y.

16.

Differential regulation of PKD isoforms in oxidative stress conditions through phosphorylation of a conserved Tyr in the P+1 loop.

Cobbaut M, Derua R, Döppler H, Lou HJ, Vandoninck S, Storz P, Turk BE, Seufferlein T, Waelkens E, Janssens V, Van Lint J.

Sci Rep. 2017 Apr 20;7(1):887. doi: 10.1038/s41598-017-00800-w.

17.

Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.

Haesen D, Abbasi Asbagh L, Derua R, Hubert A, Schrauwen S, Hoorne Y, Amant F, Waelkens E, Sablina A, Janssens V.

Cancer Res. 2016 Oct 1;76(19):5719-5731. Epub 2016 Aug 2.

18.

PP2A binds to the LIM domains of lipoma-preferred partner through its PR130/B″ subunit to regulate cell adhesion and migration.

Janssens V, Zwaenepoel K, Rossé C, Petit MM, Goris J, Parker PJ.

J Cell Sci. 2016 Apr 15;129(8):1605-18. doi: 10.1242/jcs.175778. Epub 2016 Mar 4.

19.

SHIP2 controls plasma membrane PI(4,5)P2 thereby participating in the control of cell migration in 1321 N1 glioblastoma cells.

Elong Edimo W, Ghosh S, Derua R, Janssens V, Waelkens E, Vanderwinden JM, Robe P, Erneux C.

J Cell Sci. 2016 Mar 15;129(6):1101-14. doi: 10.1242/jcs.179663. Epub 2016 Jan 29.

20.

Hematopoietic Stem Cells Transplantation Can Normalize Thyroid Function in a Cystinosis Mouse Model.

Gaide Chevronnay HP, Janssens V, Van Der Smissen P, Rocca CJ, Liao XH, Refetoff S, Pierreux CE, Cherqui S, Courtoy PJ.

Endocrinology. 2016 Apr;157(4):1363-71. doi: 10.1210/en.2015-1762. Epub 2016 Jan 26.

21.

B56δ-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.

Houge G, Haesen D, Vissers LE, Mehta S, Parker MJ, Wright M, Vogt J, McKee S, Tolmie JL, Cordeiro N, Kleefstra T, Willemsen MH, Reijnders MR, Berland S, Hayman E, Lahat E, Brilstra EH, van Gassen KL, Zonneveld-Huijssoon E, de Bie CI, Hoischen A, Eichler EE, Holdhus R, Steen VM, Døskeland SO, Hurles ME, FitzPatrick DR, Janssens V.

J Clin Invest. 2015 Aug 3;125(8):3051-62. doi: 10.1172/JCI79860. Epub 2015 Jul 13.

22.

A mouse model suggests two mechanisms for thyroid alterations in infantile cystinosis: decreased thyroglobulin synthesis due to endoplasmic reticulum stress/unfolded protein response and impaired lysosomal processing.

Gaide Chevronnay HP, Janssens V, Van Der Smissen P, Liao XH, Abid Y, Nevo N, Antignac C, Refetoff S, Cherqui S, Pierreux CE, Courtoy PJ.

Endocrinology. 2015 Jun;156(6):2349-64. doi: 10.1210/en.2014-1672. Epub 2015 Mar 26.

23.

The Basic Biology of PP2A in Hematologic Cells and Malignancies.

Haesen D, Sents W, Lemaire K, Hoorne Y, Janssens V.

Front Oncol. 2014 Dec 11;4:347. doi: 10.3389/fonc.2014.00347. eCollection 2014. Review.

24.

Time course of pathogenic and adaptation mechanisms in cystinotic mouse kidneys.

Gaide Chevronnay HP, Janssens V, Van Der Smissen P, N'Kuli F, Nevo N, Guiot Y, Levtchenko E, Marbaix E, Pierreux CE, Cherqui S, Antignac C, Courtoy PJ.

J Am Soc Nephrol. 2014 Jun;25(6):1256-69. doi: 10.1681/ASN.2013060598. Epub 2014 Feb 13.

25.

Protein phosphatase 2A regulates deoxycytidine kinase activity via Ser-74 dephosphorylation.

Amsailale R, Beyaert M, Smal C, Janssens V, Van Den Neste E, Bontemps F.

FEBS Lett. 2014 Mar 3;588(5):727-32. doi: 10.1016/j.febslet.2014.01.016. Epub 2014 Jan 23.

26.

PP2A regulatory subunit Bα controls endothelial contractility and vessel lumen integrity via regulation of HDAC7.

Martin M, Geudens I, Bruyr J, Potente M, Bleuart A, Lebrun M, Simonis N, Deroanne C, Twizere JC, Soubeyran P, Peixoto P, Mottet D, Janssens V, Hofmann WK, Claes F, Carmeliet P, Kettmann R, Gerhardt H, Dequiedt F.

EMBO J. 2013 Sep 11;32(18):2491-503. doi: 10.1038/emboj.2013.187. Epub 2013 Aug 16.

27.

Structure, regulation, and pharmacological modulation of PP2A phosphatases.

Lambrecht C, Haesen D, Sents W, Ivanova E, Janssens V.

Methods Mol Biol. 2013;1053:283-305. doi: 10.1007/978-1-62703-562-0_17. Review.

PMID:
23860660
28.

Class III phosphoinositide 3-kinase/VPS34 and dynamin are critical for apical endocytic recycling.

Carpentier S, N'Kuli F, Grieco G, Van Der Smissen P, Janssens V, Emonard H, Bilanges B, Vanhaesebroeck B, Gaide Chevronnay HP, Pierreux CE, Tyteca D, Courtoy PJ.

Traffic. 2013 Aug;14(8):933-48. doi: 10.1111/tra.12079. Epub 2013 Jun 3.

29.

Transgenic zebrafish illuminate the dynamics of thyroid morphogenesis and its relationship to cardiovascular development.

Opitz R, Maquet E, Huisken J, Antonica F, Trubiroha A, Pottier G, Janssens V, Costagliola S.

Dev Biol. 2012 Dec 15;372(2):203-16. doi: 10.1016/j.ydbio.2012.09.011. Epub 2012 Sep 26.

30.

Cacnb4 directly couples electrical activity to gene expression, a process defective in juvenile epilepsy.

Tadmouri A, Kiyonaka S, Barbado M, Rousset M, Fablet K, Sawamura S, Bahembera E, Pernet-Gallay K, Arnoult C, Miki T, Sadoul K, Gory-Faure S, Lambrecht C, Lesage F, Akiyama S, Khochbin S, Baulande S, Janssens V, Andrieux A, Dolmetsch R, Ronjat M, Mori Y, De Waard M.

EMBO J. 2012 Sep 12;31(18):3730-44. doi: 10.1038/emboj.2012.226. Epub 2012 Aug 14.

31.

Reversible Ser/Thr SHIP phosphorylation: a new paradigm in phosphoinositide signalling?: Targeting of SHIP1/2 phosphatases may be controlled by phosphorylation on Ser and Thr residues.

Edimo WE, Janssens V, Waelkens E, Erneux C.

Bioessays. 2012 Aug;34(8):634-42. doi: 10.1002/bies.201100195. Epub 2012 May 29.

PMID:
22641604
32.

The biogenesis of active protein phosphatase 2A holoenzymes: a tightly regulated process creating phosphatase specificity.

Sents W, Ivanova E, Lambrecht C, Haesen D, Janssens V.

FEBS J. 2013 Jan;280(2):644-61. doi: 10.1111/j.1742-4658.2012.08579.x. Epub 2012 Apr 25. Review.

33.
34.

PP1 and PP2A phosphatases--cooperating partners in modulating retinoblastoma protein activation.

Kolupaeva V, Janssens V.

FEBS J. 2013 Jan;280(2):627-43. doi: 10.1111/j.1742-4658.2012.08511.x. Epub 2012 Feb 29. Review.

35.

Glucose-induced posttranslational activation of protein phosphatases PP2A and PP1 in yeast.

Castermans D, Somers I, Kriel J, Louwet W, Wera S, Versele M, Janssens V, Thevelein JM.

Cell Res. 2012 Jun;22(6):1058-77. doi: 10.1038/cr.2012.20. Epub 2012 Jan 31.

36.

Deletion of the RNaseIII enzyme dicer in thyroid follicular cells causes hypothyroidism with signs of neoplastic alterations.

Rodriguez W, Jin L, Janssens V, Pierreux C, Hick AC, Urizar E, Costagliola S.

PLoS One. 2012;7(1):e29929. doi: 10.1371/journal.pone.0029929. Epub 2012 Jan 5.

37.

Suppression of scant identifies Endos as a substrate of greatwall kinase and a negative regulator of protein phosphatase 2A in mitosis.

Rangone H, Wegel E, Gatt MK, Yeung E, Flowers A, Debski J, Dadlez M, Janssens V, Carpenter AT, Glover DM.

PLoS Genet. 2011 Aug;7(8):e1002225. doi: 10.1371/journal.pgen.1002225. Epub 2011 Aug 11.

38.

Evidence of SHIP2 Ser132 phosphorylation, its nuclear localization and stability.

Elong Edimo W, Derua R, Janssens V, Nakamura T, Vanderwinden JM, Waelkens E, Erneux C.

Biochem J. 2011 Nov 1;439(3):391-401. doi: 10.1042/BJ20110173.

PMID:
21770892
39.

Molecular implication of PP2A and Pin1 in the Alzheimer's disease specific hyperphosphorylation of Tau.

Landrieu I, Smet-Nocca C, Amniai L, Louis JV, Wieruszeski JM, Goris J, Janssens V, Lippens G.

PLoS One. 2011;6(6):e21521. doi: 10.1371/journal.pone.0021521. Epub 2011 Jun 23.

40.

Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta.

Louis JV, Martens E, Borghgraef P, Lambrecht C, Sents W, Longin S, Zwaenepoel K, Pijnenborg R, Landrieu I, Lippens G, Ledermann B, Götz J, Van Leuven F, Goris J, Janssens V.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6957-62. doi: 10.1073/pnas.1018777108. Epub 2011 Apr 11.

41.

Live-cell imaging RNAi screen identifies PP2A-B55alpha and importin-beta1 as key mitotic exit regulators in human cells.

Schmitz MH, Held M, Janssens V, Hutchins JR, Hudecz O, Ivanova E, Goris J, Trinkle-Mulcahy L, Lamond AI, Poser I, Hyman AA, Mechtler K, Peters JM, Gerlich DW.

Nat Cell Biol. 2010 Sep;12(9):886-93. doi: 10.1038/ncb2092. Epub 2010 Aug 15.

42.

PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR.

Yan L, Mieulet V, Burgess D, Findlay GM, Sully K, Procter J, Goris J, Janssens V, Morrice NA, Lamb RF.

Mol Cell. 2010 Mar 12;37(5):633-42. doi: 10.1016/j.molcel.2010.01.031.

43.

The Accelerating Access Initiative: experience with a multinational workplace programme in Africa.

Van der Borght S, Janssens V, Schim van der Loeff MF, Kajemba A, Rijckborst H, Lange JM, Rinke de Wit TF.

Bull World Health Organ. 2009 Oct;87(10):794-8.

44.
45.

Specific regulation of protein phosphatase 2A PR72/B'' subunits by calpain.

Janssens V, Derua R, Zwaenepoel K, Waelkens E, Goris J.

Biochem Biophys Res Commun. 2009 Sep 4;386(4):676-81. doi: 10.1016/j.bbrc.2009.06.096. Epub 2009 Jun 23.

PMID:
19555667
46.

Targeted disruption of the mouse Lipoma Preferred Partner gene.

Vervenne HB, Crombez KR, Delvaux EL, Janssens V, Van de Ven WJ, Petit MM.

Biochem Biophys Res Commun. 2009 Feb 6;379(2):368-73. doi: 10.1016/j.bbrc.2008.12.074. Epub 2008 Dec 26.

PMID:
19111675
47.

Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa.

Zachariah R, Ford N, Philips M, Lynch S, Massaquoi M, Janssens V, Harries AD.

Trans R Soc Trop Med Hyg. 2009 Jun;103(6):549-58. doi: 10.1016/j.trstmh.2008.09.019. Epub 2008 Nov 6. Review.

PMID:
18992905
48.

Diversity in genomic organisation, developmental regulation and distribution of the murine PR72/B" subunits of protein phosphatase 2A.

Zwaenepoel K, Louis JV, Goris J, Janssens V.

BMC Genomics. 2008 Aug 20;9:393. doi: 10.1186/1471-2164-9-393.

49.

Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease.

Bueno de Mesquita M, Ferrante M, Henckaerts L, Joossens M, Janssens V, Hlavaty T, Pierik M, Joossens S, Van Schuerbeek N, Van Assche G, Rutgeerts P, Vermeire S, Hoffman I.

Eur J Pediatr. 2009 May;168(5):575-83. doi: 10.1007/s00431-008-0798-7. Epub 2008 Aug 1.

PMID:
18670786
50.

Protein phosphatase 2A controls the activity of histone deacetylase 7 during T cell apoptosis and angiogenesis.

Martin M, Potente M, Janssens V, Vertommen D, Twizere JC, Rider MH, Goris J, Dimmeler S, Kettmann R, Dequiedt F.

Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4727-32. doi: 10.1073/pnas.0708455105. Epub 2008 Mar 13.

Supplemental Content

Loading ...
Support Center